(lp0
S'Zacks: Pain Therapeutics, Inc.  Given Consensus Rating of Hold by Analysts BNB Daily  - 9 hours ago Pain Therapeutics logo Pain Therapeutics, Inc.  has been assigned a consensus broker rating score of 3.00  from the one brokers that cover the company, Zacks Investment Research reports.'
p1
aS'Pain Therapeutics to Discuss REMOXY ER with FDA GlobeNewswire  - Dec 20, 2016 AUSTIN, Texas, Dec. 20, 2016  -- Pain Therapeutics, Inc.  today announced it plans to meet with the U.S.'
p2
aS'Pain Therapeutics Reports 2016 Financial Results GlobeNewswire  - Feb 17, 2017 AUSTIN, Texas, Feb. 17, 2017  -- Pain Therapeutics, Inc.  today reported financial results for the year ended December 31, 2016 and provided an update on recent developments.'
p3
aS"View the Stunning Stock of Pain Therapeutics, Inc.'s  stock price is ... Hot Stocks Point - 6 hours ago Pain Therapeutics, Inc. , a part of Healthcare sector and belongs to Biotechnology industry; ended its day with loss -0.83% and finalized at the price of $0.70."
p4
aS"Today Analysts Focus on CEL-SCI Corporation , Pain Therapeutics, Inc.  StockNewsJournal - Mar 14, 2017 Pain Therapeutics, Inc. , maintained return on investment for the last twelve months at -61.87, higher than what Reuters data shows regarding industry's average.Two Biotech Stocks Are Just So Hot Right Now: CEL-SCI Corporation , Pain ... - The Independent Republic"
p5
aS'Pain Therapeutics Gets Nod On $8.5M Remoxy Class Deal Law360  - Sep 2, 2016 Law360, Dallas  -- A Texas federal judge on Thursday gave preliminary approval of a settlement that would pay shareholders of Pain Therapeutics Inc. up to $8.5 million and release claims the company hid from the market&nbsp;...'
p6
aS"Stock Update : Here's Why Pain Therapeutics, Inc.'s Stock Plunged ... Smarter Analyst - Sep 26, 2016 Pain Therapeutics, Inc.  saw its shares crater over 50% today on exceptionally high volume. This drop was triggered by the announcement that the U.S.For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million - TheStreet.comComplete Response Letter for REMOXY - GlobeNewswire "
p7
aS'Intellipharmaceutics Competitive Opportunity Gets A Boost From Pain ... Seeking Alpha - Oct 6, 2016 Intellipharmaceutics  received a boost to its competitive position with the FDA advising one of its primary competitors, Pain Therapeutics, Inc.  that they will be required to submit additional clinical data if they wish to ...'
p8
aS"Pain Therapeutics receives FDA letter saying NDA for opioid analgesic can't be ... MarketWatch - Sep 26, 2016 Pain Therapeutics Inc. PTIE, +4.04% said Monday it received a complete response letter from the Food and Drug Administration saying its new drug application for the opioid Remoxy ER could not be approved in its present form."
p9
aS"Here's What The Latest Pain Therapeutics, Inc.  Update Means Market Exclusive - Feb 21, 2017 Pain Therapeutics, Inc.  put out a fourth-quarter business update, and alongside it, gave us some insight into the possible future of the company's long suffering abuse deterrent asset, Remoxy.Analysts Near-Term outlook: Pain Therapeutics, Inc. , Sealed Air ... - The USA Commerce"
p10
a.